European Partnership for Action Against Cancer (EPAAC) D9: Reducing inequalities in cancer treatment and care through the use of clinical guidelines: A review and evidence-based recommendations

First Page		Document Content
Date: 2014-06-17 07:30:29 Cancer organizations Health promotion Cancer screening Cancer Pathology Medical guideline Stomach cancer Breast cancer Health equity Medicine Health Medical terms		European Partnership for Action Against Cancer (EPAAC) D9: Reducing inequalities in cancer treatment and care through the use of clinical guidelines: A review and evidence-based recommendations Add to Reading List Source URL: www.epaac.eu Download Document from Source Website File Size: 955,16 KB Share Document on Facebook

	Journal of Machine Learning ResearchSubmitted 8/15; Revised 3/16; PublishedStructure-Leveraged Methods in Breast Cancer Risk Prediction DocID: 1vq0d - View Document
	Multicausality: Confounding - Assignment solutions 1. a. Reserpine is a risk factor. Overall, the incidence of breast cancer isper 100,000 women-years in reserpine users and 6.14 per 100,000 women-years in nonuser DocID: 1vpNA - View Document
	Frequently Asked Questions: Trainees seeking a PhD education in Cancer Biology or a related area with a focus on Breast Cancer Health Disparities. 1. What is the Komen Graduate Training in Disparities Research Grant (GT DocID: 1voV1 - View Document
	_____________________________________________________________ What to Do When Someone You Know Has Been Diagnosed with Breast Cancer [Last revised Mar 2014] DocID: 1vlqg - View Document
	Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1–mediated metabolism to the product 4′ hydroxy tangeretin DocID: 1vl9e - View Document